Departure of Nephropathy, People's Hospital of Wuwei Gansu Province, Weiwu 733000, Gansu, PR China.
Emergency Department of Orthopedics, Gansu Provincial Hospital of TCM, Lanzhou 730000, Gansu, PR China.
J Nanosci Nanotechnol. 2020 Oct 1;20(10):6555-6560. doi: 10.1166/jnn.2020.18576.
In this study, our aim is to investigate the effect of lanthanum carbonate in chronic treatment renal failure complicated with hyperphosphatemia. Using methods with lanthanum carbonate, hyperphosphatemia, placebos, calcium carbonate, end-stage renal disease as keywords, we searched the Chinese Journal Full-text Database, Chinese sci-tech journal database, Wanfang Data knowledge service platform, web of science, PubMed, and other databases for literature quality; meta analysis was carried out after a subsequent evaluation. The meta analysis results showed a significant difference in the control of the blood phosphorus level between weighted mean difference WMD = -0.60, 95% CI: -0.75-0.45, lanthanum carbonate and placebo; WMD = -0.01, 95% CI: -0.07-0.05; the lanthanum carbonate and placebo had no significant difference in the control of the blood calcium levels after treatment; WMD = -29.75, 95% CI: -39.22 for the control of blood PIH level after treatment, indicating that the difference between lanthanum carbonate and placebo in the control of the parathyroid hormone (PTH) level was statistically significant. WMD=0.41, 95% CI: -0.480.34; the difference between the lanthanum carbonate and calcium carbonate in the control of the blood phosphorus level was statistically significant; WMD = 0.19, 95% CI: -0.250.13, lanthanum carbonate and calcium carbonate were statistically significant in blood control calcium level; WMD = 174.66, 95% CI: -150.86~150.46, lanthanum carbonate and calcium carbonate were statistically significant in the control of blood PIH level; the difference was statistically significant. : Lanthanum carbonate can significantly reduce blood phosphorus and PIH complicated hyperphosphatemia, and has no significant effect on blood calcium, which is superior to calcium carbonate in effectiveness.
在这项研究中，我们的目的是研究碳酸镧在慢性肾衰竭合并高磷血症的治疗中的作用。使用碳酸镧、高磷血症、安慰剂、碳酸钙、终末期肾病作为关键词，我们在中国期刊全文数据库、中国科技期刊数据库、万方数据知识服务平台、Web of Science、PubMed 等数据库中检索文献质量；随后进行了荟萃分析。荟萃分析结果显示，碳酸镧与安慰剂相比，在控制血磷水平方面存在显著差异（加权均数差 WMD = -0.60，95%CI：-0.75-0.45）；WMD = -0.01，95%CI：-0.07-0.05）；治疗后，碳酸镧与安慰剂在控制血钙水平方面无显著差异；WMD = -29.75，95%CI：-39.22 治疗后血 PIH 水平的控制，表明碳酸镧与安慰剂在甲状旁腺激素（PTH）水平的控制上存在显著差异。WMD=0.41，95%CI：-0.480.34）；碳酸镧与碳酸钙在控制血磷水平方面存在显著差异；WMD = 0.19，95%CI：-0.250.13，碳酸镧与碳酸钙在控制血钙水平方面有统计学意义；WMD = 174.66，95%CI：-150.86~150.46，碳酸镧与碳酸钙在控制血 PIH 水平方面有统计学意义；差异有统计学意义。：碳酸镧能显著降低高磷血症合并高磷血症患者的血磷和 PIH，对血钙无明显影响，在疗效上优于碳酸钙。
